Foghorn Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>FT</div>
FHTX -- USA Stock  

USD 10.77  0.73  6.35%

As many of us are excited about healthcare space, it is fair to break down Foghorn Therapeutics within current market trends. Although for some short-term oriented investors Foghorn Therapeutics may not be the right move right now, but if you are here for the long run, it may a good chance to get in. The returns on the market and returns on Foghorn Therapeutics appear slightly correlated for the last few months. The appearance of strong basic indicators of the company suggests a short-term price swing for investors of Foghorn. The stock experiences an active upward rally.
Published over a month ago
View all stories for Foghorn Therapeutics | View All Stories
Is Foghorn (NASDAQ:FHTX) outlook still optimistic?
The firm's average rating is Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Foghorn Therapeutics market sentiment investors' perception of the future value of Foghorn. Let us look at a few aspects of Foghorn technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Foghorn Therapeutics. In general, we focus on analyzing Foghorn Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Foghorn Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Foghorn Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Foghorn Therapeutics, we also check how macroeconomic factors affect Foghorn Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Foghorn Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Foghorn Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Foghorn Therapeutics. Your research has to be compared to or analyzed against Foghorn Therapeutics' peers to derive any actionable benefits. When done correctly, Foghorn Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Foghorn Therapeutics.

How does Foghorn Stands against Peers?

Analyzing Foghorn Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Foghorn Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Foghorn Therapeutics Competition Details

How Foghorn utilizes its cash?

To perform a cash flow analysis of Foghorn Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Foghorn Therapeutics is receiving and how much cash it distributes out in a given period. The Foghorn Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Foghorn Therapeutics Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Foghorn Therapeutics reported Net Cash Flow from Operations of (31.29 Million) in 2020

Acquisition by Decicco Carl of 100000 shares of Foghorn Therapeutics subject to Rule 16b-3

Legal trades by Foghorn Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Foghorn insider trading alert for grant of stock option (right to buy) by Decicco Carl, Chief Scientific Officer, on 1st of February 2021. This event was filed by Foghorn Therapeutics Inc with SEC on 2021-02-01. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Foghorn Therapeutics

Foghorn Therapeutics has a beta of 0.6785. Let's try to break down what Foghorn's beta means in this case. The returns on MARKET and Foghorn Therapeutics are completely uncorrelated. The beta indicator helps investors understand whether Foghorn Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Foghorn deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
The big decline in price over the last few months for Foghorn Therapeutics could raise concerns from investors as the firm it trading at a share price of 14.11 on 251,974 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in February. However, diversifying your holdings with Foghorn Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.48. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Foghorn Therapeutics partners.

Will Foghorn Therapeutics current rise continue?

The potential upside is down to 6.01 as of today. Foghorn Therapeutics exhibits very low volatility with skewness of -0.45 and kurtosis of 1.6. However, we advise investors to further study Foghorn Therapeutics technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Foghorn Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Foghorn Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Foghorn Therapeutics

While many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Foghorn Therapeutics may offer a potential longer-term growth to investors. Taking everything into account, as of the 19th of March 2021, our analysis shows that Foghorn Therapeutics follows the market closely. The company is undervalued and projects below average probability of distress for the next 2 years. Our current 30 days buy-hold-sell recommendation on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Foghorn Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to